Efectividad del tratamiento con agentes antivirales directos en pacientes con coinfección por VHC y VIH.Estudio de cohorte multicéntrico
- David Rial Crestelo 1
- Miguel Rodríguez Cola 2
- Francisco Javier González Gasca
- Paloma Geijo Martínez
- Olga Belinchón Moya
- Elisa Martínez Alfaro
- Fernando Mateos Rodríguez
- José Ramón Barberá
- Miguel Yzusqui
- Sonia Casallo
- María García
- Alfredo Espinosa-Gimeno 1
- Miguel Torralba 1
-
1
Hospital Universitario de Guadalajara
info
-
2
Hospital Virgen de la Salud
info
ISSN: 2340-4167, 1130-0108
Year of publication: 2018
Volume: 110
Issue: 1
Pages: 35-43
Type: Article
More publications in: Revista Española de Enfermedades Digestivas
Sustainable development goals
Abstract
Introduction: The effectiveness of direct-acting antiviral (DAA) agents has been demonstrated in clinical trials both in patients with mono and coinfections. The goal of the study was to analyze the effectiveness and toxicity of this therapy in real-life patients with a HIV/HCV coinfection and to identify variables that are associated with an unfavorable outcome. Methods: This was a multicenter ambispective study in a cohort of coinfected patients. Data were collected from eight centers in Castilla-La Mancha from 2014 to 2016. An intent-to-treat analysis was performed and any loss to follow-up, treatment withdrawal or toxicity was considered as a failure. Results: A total of 229 patients were included with a median age of 49.6 years and the majority were male (83%). Fewer than 10% had a detectable HIV-related viral load (VL). The most prevalent HCV genotype was 1 (65.1%). Fifty percent had cirrhotic liver disease and 65% had over 800,000 copies/ml of HCV VL. The global sustained viral response (SVR) was reached by 91.7% of cases. The most commonly used DAA regimen was sofosbuvir/ledipasvir. Ribavirin was included in 52% of regimens, 65.9% of cases completed 12-week regimens and 30% completed 24-week schemes. There were 19 therapy failures. No differences were observed between the various DAA strategies used. No independent predictor was found for SVR. Conclusions: HCV treatment in coinfected patients is highly successful in terms of SVR rate in the real-life setting and toxicity is exceptional. We identified no specific predictors of an unfavorable outcome.